Regeneron Pharmaceuticals (NASDAQ:REGN) Earns Neutral Rating from Cantor Fitzgerald

Regeneron Pharmaceuticals (NASDAQ:REGN)‘s stock had its “neutral” rating restated by equities research analysts at Cantor Fitzgerald in a report released on Monday, Benzinga reports. They presently have a $1,015.00 target price on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price target would suggest a potential downside of 10.68% from the stock’s previous close.

Other research analysts have also recently issued reports about the stock. Barclays raised their target price on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,220.00 and gave the stock an “overweight” rating in a report on Friday, August 2nd. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $1,250.00 price objective on shares of Regeneron Pharmaceuticals in a report on Thursday, September 5th. Piper Sandler increased their target price on Regeneron Pharmaceuticals from $1,166.00 to $1,242.00 and gave the stock an “overweight” rating in a report on Friday, August 23rd. Wells Fargo & Company raised their price target on Regeneron Pharmaceuticals from $1,125.00 to $1,200.00 and gave the stock an “overweight” rating in a research report on Friday, August 2nd. Finally, Argus upped their price objective on shares of Regeneron Pharmaceuticals from $1,060.00 to $1,170.00 and gave the stock a “buy” rating in a research report on Tuesday, June 25th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, sixteen have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $1,109.70.

Regeneron Pharmaceuticals Stock Performance

Shares of NASDAQ REGN opened at $1,136.35 on Monday. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.44 and a quick ratio of 4.62. The firm has a market cap of $125.27 billion, a price-to-earnings ratio of 33.57, a P/E/G ratio of 3.86 and a beta of 0.12. The stock’s fifty day moving average price is $1,116.69 and its two-hundred day moving average price is $1,023.01. Regeneron Pharmaceuticals has a one year low of $769.19 and a one year high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 EPS for the quarter, beating the consensus estimate of $8.93 by $2.63. Regeneron Pharmaceuticals had a net margin of 32.04% and a return on equity of 16.80%. The business had revenue of $3.55 billion for the quarter, compared to the consensus estimate of $3.38 billion. During the same period in the prior year, the company posted $8.79 earnings per share. Regeneron Pharmaceuticals’s revenue was up 12.3% compared to the same quarter last year. On average, equities analysts forecast that Regeneron Pharmaceuticals will post 37.8 EPS for the current year.

Insider Activity

In related news, Director Arthur F. Ryan sold 100 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Monday, July 1st. The shares were sold at an average price of $1,059.24, for a total transaction of $105,924.00. Following the sale, the director now directly owns 17,882 shares in the company, valued at approximately $18,941,329.68. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In other news, CFO Christopher R. Fenimore sold 5,680 shares of the firm’s stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the completion of the transaction, the chief financial officer now directly owns 15,305 shares in the company, valued at $18,447,575.65. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Arthur F. Ryan sold 100 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $1,059.24, for a total value of $105,924.00. Following the completion of the transaction, the director now directly owns 17,882 shares in the company, valued at $18,941,329.68. The disclosure for this sale can be found here. Over the last three months, insiders have sold 11,561 shares of company stock valued at $13,095,105. 7.48% of the stock is currently owned by corporate insiders.

Institutional Trading of Regeneron Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Gilbert & Cook Inc. raised its stake in Regeneron Pharmaceuticals by 8.3% during the fourth quarter. Gilbert & Cook Inc. now owns 1,907 shares of the biopharmaceutical company’s stock worth $1,675,000 after buying an additional 146 shares during the last quarter. Principal Securities Inc. bought a new position in shares of Regeneron Pharmaceuticals in the 4th quarter worth about $280,000. AGF Management Ltd. acquired a new position in shares of Regeneron Pharmaceuticals in the 4th quarter valued at about $639,000. Qsemble Capital Management LP bought a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter valued at about $210,000. Finally, Envestnet Portfolio Solutions Inc. boosted its position in shares of Regeneron Pharmaceuticals by 45.2% during the 4th quarter. Envestnet Portfolio Solutions Inc. now owns 1,188 shares of the biopharmaceutical company’s stock valued at $1,043,000 after purchasing an additional 370 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.